Benign Prostatic Hyperplasia (BPH)

1. Clinical Overview

Summary

Benign prostatic hyperplasia (BPH) is a non-malignant proliferative condition characterized by stromal and epithelial cell hyperplasia in the transition zone of the prostate gland. As the most common benign neoplasm in aging men, BPH affects over 50% of men by age 60 and more than 90% by age 85. [1] The enlarging prostate compresses the prostatic urethra, leading to lower urinary tract symptoms (LUTS) that significantly impact quality of life. LUTS are categorized into voiding symptoms (hesitancy, weak stream, straining, incomplete emptying, terminal dribbling) and storage symptoms (frequency, urgency, nocturia, urgency incontinence). [2]

The pathophysiology involves both static and dynamic components: the static component arises from physical urethral compression by hyperplastic tissue, while the dynamic component reflects increased smooth muscle tone mediated by alpha-1 adrenergic receptors in the prostate and bladder neck. [3] Dihydrotestosterone (DHT), converted from testosterone by 5-alpha reductase, is the primary androgenic driver of prostatic growth.

Clinical assessment relies on the International Prostate Symptom Score (IPSS), which stratifies severity into mild (0-7), moderate (8-19), and severe (20-35) categories and guides management decisions. [4] Digital rectal examination (DRE) differentiates benign smooth enlargement from suspicious nodular findings. Serum prostate-specific antigen (PSA) helps exclude malignancy but is often elevated in BPH proportional to gland volume.

Management is tailored to symptom severity and complications. Mild symptoms warrant watchful waiting with lifestyle modifications. Medical therapy includes alpha-blockers (tamsulosin, alfuzosin) for rapid symptomatic relief and 5-alpha reductase inhibitors (5-ARIs: finasteride, dutasteride) to reduce prostate volume and long-term progression risk. [5,6] Combination therapy provides superior outcomes for larger prostates. Surgical intervention (TURP, HoLEP, UroLift, Rezum) is indicated for refractory symptoms, recurrent retention, renal impairment, bladder stones, or recurrent urinary tract infections.

Key Facts

• Epidemiology: Histological BPH present in 50% of men at age 50, rising to 90% by age 80; symptomatic moderate-severe LUTS affect 25-30% of men over 55 [1,2]
• Pathophysiology: Hyperplasia in transition zone driven by DHT; both static (physical) and dynamic (alpha-adrenergic tone) obstruction [3]
• Symptom assessment: IPSS standardized questionnaire (0-7 mild, 8-19 moderate, 20-35 severe) plus quality of life score [4]
• Diagnostic triad: IPSS, DRE (smooth vs nodular), PSA (interpret with prostate volume)
• First-line medical: Alpha-blockers (tamsulosin 0.4 mg daily) — symptomatic improvement within days to weeks [7]
• Second-line medical: 5-ARIs (finasteride 5 mg, dutasteride 0.5 mg) — reduce volume by 20-30% over 6-12 months [8]
• Combination therapy: Alpha-blocker + 5-ARI superior for prostates > 30-40 mL and PSA > 1.5 ng/mL [6]
• Gold standard surgery: TURP achieves 70-80% symptom improvement; HoLEP equally effective with less bleeding [9,10]

Clinical Pearls

IPSS Drives Decision-Making: The IPSS is both diagnostic and prognostic. Mild symptoms (0-7) with low bother scores can be managed expectantly. Moderate-severe scores (≥8) warrant medical therapy. Use serial IPSS to track treatment response.

Combination Therapy for Large Glands: Men with prostate volume > 30-40 mL, PSA > 1.5 ng/mL, or severe symptoms benefit most from alpha-blocker + 5-ARI combination, which reduces acute urinary retention (AUR) risk by 66% compared to placebo. [6]

Alpha-Blockers Work Fast, 5-ARIs Work Slow: Tamsulosin provides symptom relief within 48-72 hours. Finasteride/dutasteride require 3-6 months for prostate shrinkage but reduce long-term progression and AUR incidence by ~50%. [8,11]

Exclude Prostate Cancer: A hard, asymmetric, or nodular prostate on DRE mandates imaging (MRI prostate) and potential biopsy, regardless of PSA. PSA > 10 ng/mL or rapid PSA velocity (> 0.75 ng/mL/year) also raises cancer suspicion. PSA density (PSA/prostate volume) > 0.15 is concerning. [12]

Watch for 5-ARI Effect on PSA: Finasteride and dutasteride reduce PSA by approximately 50% after 6-12 months. Double the measured PSA value to assess cancer risk in men on chronic 5-ARI therapy. [13]

Recognize Chronic Retention: Unlike painful acute retention, chronic high-pressure retention is painless, with large bladder volumes (often > 1000 mL), bilateral hydronephrosis, and elevated creatinine. It requires prolonged catheter drainage before definitive surgery to allow renal recovery.

Why This Matters Clinically

BPH is the most common cause of LUTS in men over 50 and represents a major public health burden. Untreated BPH can progress to acute urinary retention (2-3% annual risk without treatment), chronic retention with obstructive nephropathy, recurrent UTIs, bladder calculi, and gross hematuria. [14] Moderate-severe LUTS significantly impair quality of life, sleep quality (due to nocturia), and mental health. Evidence-based treatment substantially improves symptoms, prevents complications, and reduces need for emergency intervention. Early identification and tailored management are key to optimizing outcomes.

---

2. Epidemiology

Prevalence

BPH exhibits age-dependent prevalence with near-universal histological evidence in elderly men:

• Histological BPH (autopsy/pathological studies): 20% at age 40, 50% at age 50, 70% at age 70, and > 90% at age 80 [1]
• Clinical BPH (symptomatic LUTS): 25-30% of men over 55 have moderate-severe symptoms [2]
• Treated BPH: Approximately 10-15% of men seek medical treatment for LUTS by age 70

The discrepancy between histological and clinical BPH highlights that not all prostatic enlargement produces symptoms, and symptom severity correlates poorly with prostate size.

Incidence

• Annual incidence of moderate-severe LUTS: 4-5 per 1000 men aged 40-49, rising to 25-30 per 1000 men over 70 [2]
• Acute urinary retention: Incidence 6.8 per 1000 men-years (ages 60-69), increasing to 34.7 per 1000 men-years (ages 80+) [14]
• Surgical intervention: Annual incidence of prostate surgery ~3.5 per 1000 men over 50

Demographics and Risk Factors

Protective Factors

• Androgen deprivation (medical or surgical castration): Prevents BPH development and causes existing BPH regression
• Regular physical activity: Modest protective effect
• Healthy diet: Limited evidence for protective role of specific foods

---

3. Pathophysiology

Molecular and Cellular Mechanisms

BPH pathogenesis is multifactorial, involving hormonal, cellular, and inflammatory processes:

Hormonal Drivers

Dihydrotestosterone (DHT) Pathway:

• Testosterone is converted to DHT by 5-alpha reductase (type 2 isoenzyme predominates in prostate)
• DHT binds to androgen receptors with 5-fold greater affinity than testosterone
• DHT-androgen receptor complexes translocate to nucleus and activate transcription of growth-promoting genes
• DHT stimulates both stromal and epithelial cell proliferation, inhibits apoptosis, and promotes extracellular matrix deposition [3]

Estrogen Role:

• Age-related decline in testosterone with relatively preserved estrogen levels increases estrogen/androgen ratio
• Estrogens potentiate androgen receptor expression and may promote stromal proliferation [1]

Cellular Hyperplasia

Transition Zone Growth:

• BPH originates in the transition zone (periurethral region), unlike prostate cancer which typically arises in the peripheral zone
• Nodular hyperplasia of both stromal (smooth muscle, fibroblasts) and glandular (epithelial) components
• Stromal hyperplasia predominates in most BPH (ratio ~5:1 stroma to epithelium) [3]

Proliferation-Apoptosis Imbalance:

• Increased cell proliferation is modest; decreased apoptosis (programmed cell death) is more significant
• Growth factors (FGF, TGF-beta, IGF) promote cell survival and proliferation
• Stem cell reactivation in transition zone may drive continuous growth [1]

Inflammation

• Chronic prostatic inflammation (lymphocytic infiltration) present in up to 40-50% of BPH specimens
• Inflammatory cytokines (IL-6, IL-8, TNF-alpha) promote fibrosis and tissue remodeling
• Inflammation correlates with larger prostate volumes and faster progression [1]

Metabolic Factors

• Metabolic syndrome (obesity, insulin resistance, dyslipidemia) associated with increased prostate volume
• Mechanisms include hyperinsulinemia promoting IGF-1, sympathetic nervous system activation, and chronic inflammation [1]

Bladder Outlet Obstruction (BOO) and Bladder Changes

Static Component (Mechanical Obstruction)

• Enlarged transition zone compresses prostatic urethra
• Median lobe enlargement can cause "ball-valve" obstruction of bladder neck
• Obstruction severity correlates poorly with prostate size (no direct size-symptom relationship)

Dynamic Component (Functional Obstruction)

• Smooth muscle in prostate stroma, capsule, and bladder neck contains alpha-1 adrenergic receptors (predominantly alpha-1A subtype)
• Sympathetic activation increases smooth muscle tone, exacerbating obstruction [3]
• This explains efficacy of alpha-blockers even without prostate shrinkage

Bladder Response to Obstruction

Compensated Phase:

1. Detrusor hypertrophy (smooth muscle thickening) to maintain voiding pressure
2. Bladder trabeculation visible on cystoscopy
3. Increased bladder wall thickness on imaging
4. Voiding symptoms predominate (hesitancy, weak stream, straining)

Decompensated Phase:

1. Detrusor fatigue and contractile failure
2. Increased post-void residual (PVR) urine
3. Bladder diverticula formation (mucosa herniates through hypertrophied muscle)
4. Chronic high-pressure retention may develop
5. Storage symptoms emerge or worsen (frequency, urgency, nocturia)
6. Risk of upper tract dilatation and renal impairment [16]

---

4. Clinical Presentation

Lower Urinary Tract Symptoms (LUTS)

LUTS are categorized into voiding (obstructive) and storage (irritative) symptoms. BPH classically causes both, though voiding symptoms typically dominate early.

Voiding Symptoms (Obstructive)

Storage Symptoms (Irritative)

International Prostate Symptom Score (IPSS)

The IPSS is a validated, 7-item questionnaire assessing LUTS severity over the past month. Each item scores 0-5 (total 0-35). An additional quality of life (QoL) question scores 0-6. [4]

IPSS Scoring Framework

IPSS Questions (Each Scored 0-5)

Quality of Life Question: "If you were to spend the rest of your life with your urinary condition the way it is now, how would you feel?" (0 = delighted, 6 = terrible)

• QoL score ≥4 indicates significant bother and warrants treatment even if IPSS is in mild-moderate range
• QoL score \u003c3 suggests patient is coping well; watchful waiting appropriate even for moderate IPSS

Validated Translations and Psychometric Properties

Psychometric Validation:

• Reliability: Cronbach's alpha 0.86 (excellent internal consistency) [4]
• Test-retest reliability: Correlation coefficient 0.92 over 2-week interval [4]
• Responsiveness: Detects changes ≥3 points as clinically meaningful improvement [25]
• Minimal clinically important difference (MCID): 3-point reduction in IPSS [25]
• Validated in 30+ languages: Cross-cultural adaptation for international use

Clinical Interpretation:

• Baseline assessment: Establish severity and guide initial treatment
• Treatment monitoring: Serial IPSS every 3-6 months on medical therapy
• Surgical candidacy: IPSS ≥20 or IPSS 8-19 with QoL ≥4 supports surgical referral
• Treatment success: ≥3-point reduction indicates meaningful response [25]

IPSS Subscores: Voiding vs Storage Symptoms

Calculate separate subscores to guide therapy:

Voiding Subscore (Questions 1, 3, 5, 6; max 20):

• Reflects bladder outlet obstruction (BOO)
• Responds well to alpha-blockers and surgical decompression
• High voiding score predicts good surgical outcome

Storage Subscore (Questions 2, 4, 7; max 15):

• Reflects detrusor overactivity (DO)
• May persist after surgery if bladder changes irreversible
• High storage score may warrant anticholinergic/beta-3 agonist addition

Clinical Application:

• Voiding-predominant (V \u003e\u003e S): Alpha-blocker monotherapy suitable
• Mixed (V ≈ S): Combination alpha-blocker + anticholinergic (if PVR \u003c100 mL)
• Storage-predominant (S \u003e\u003e V): Consider overactive bladder (OAB) as primary diagnosis; evaluate for non-BPH causes

Limitations and Complementary Assessments

IPSS Limitations:

• Not disease-specific: Elevated in urethral stricture, OAB, neurogenic bladder, prostate cancer
• No objective measures: Does not quantify PVR, Qmax, or prostate volume
• Poor size correlation: Symptom severity correlates weakly with prostate size (r = 0.2-0.3)
• Recall bias: Based on 4-week recall; frequency-volume charts more accurate for nocturia
• Cultural factors: Symptom reporting varies by ethnicity and cultural norms [26]
• Age dependency: Elderly may underreport due to acceptance as "normal aging"

Complementary Assessments:

• Uroflowmetry (Qmax): Objective BOO assessment; Qmax \u003c10 mL/s predicts surgical response
• Post-void residual (PVR): IPSS does not measure; PVR \u003e200 mL increases retention risk
• Frequency-volume chart (3-day bladder diary): Quantifies nocturia, functional capacity, polyuria
• Prostate volume (TRUS): Guides 5-ARI use (benefit if \u003e30-40 mL)
• PSA: Correlates with volume (~0.3 ng/mL per gram); PSA \u003e1.5 ng/mL predicts progression [22]

IPSS in Clinical Trials

Landmark Trials Using IPSS as Primary Endpoint:

Interpreting Trial Data:

• Alpha-blocker monotherapy: Typical IPSS reduction 4-6 points (30-40% improvement) [7]
• 5-ARI monotherapy: Typical IPSS reduction 3-5 points (20-30% improvement) [8]
• Combination therapy: Typical IPSS reduction 6-8 points (40-50% improvement) [5,6]
• TURP/HoLEP: Typical IPSS reduction 15-18 points (70-80% improvement) [9,10]

Special Considerations

IPSS in Acute Urinary Retention (AUR):

• Cannot assess during retention; use retrospective recall
• Severe pre-retention IPSS (≥20) predicts failed trial without catheter (TWOC)
• Post-catheterization IPSS guides definitive management

IPSS in Chronic Retention:

• Often paradoxically low (detrusor decompensation reduces sensation)
• Overflow symptoms may dominate (incontinence, dribbling)
• Rely more on PVR, creatinine, and imaging than IPSS

IPSS in Post-Surgical Follow-Up:

• Expect ≥70% reduction (≥15 points) after TURP/HoLEP
• Persistent high IPSS post-surgery suggests urethral stricture, bladder neck contracture, or detrusor failure
• IPSS \u003c8 at 3 months indicates successful outcome

IPSS and Prostate Cancer:

• IPSS does not screen for cancer (no discriminatory value)
• Prostate cancer patients may have normal or elevated IPSS
• Always perform DRE and PSA; do not rely on IPSS to exclude cancer

Complications of BPH

---

Acute Urinary Retention (AUR): Comprehensive Management

Definition and Classification

Acute Urinary Retention (AUR): Sudden painful inability to void despite having a full bladder, typically with volume \u003e300 mL.

AUR Classification

Distinction is Critical:

• Spontaneous AUR: Surgical intervention rate 75-90% within 1 year [30]
• Precipitated AUR: Successful TWOC in 50-70% if precipitant corrected [30]

Epidemiology and Risk Factors

Incidence by Age: [14]

• 40-49 years: 0.4 per 1000 men-years
• 50-59 years: 3.0 per 1000 men-years
• 60-69 years: 6.8 per 1000 men-years
• 70-79 years: 17.6 per 1000 men-years
• 80+ years: 34.7 per 1000 men-years

Cumulative Risk:

• 5-year risk (untreated moderate-severe BPH): 10-12%
• 10-year risk: 20-30%

Predictors of AUR in BPH Patients: [14,22,30]

Clinical Presentation and Diagnosis

Symptoms:

• Suprapubic pain: Severe, cramping; worsens with time
• Inability to void: Complete anuria despite strong urge
• Restlessness and agitation: Due to pain and distress
• Nausea: Vagal stimulation from bladder distension

Signs:

• Palpable bladder: Firm, tender, dull to percussion, extends above pubic symphysis
• Suprapubic tenderness: Direct palpation elicits pain
• DRE: Enlarged prostate (if BPH cause); normal in other causes

Bladder Scan (Ultrasound):

• Non-invasive confirmation of retention
• Volume \u003e300 mL diagnostic for AUR
• Volume \u003e500 mL indicates significant retention
• Bedside bladder scanner is first-line investigation

Differential Diagnosis of AUR:

Immediate Management: Emergency Catheterization

Initial Stabilization:

1. Analgesia: Paracetamol 1 g IV + opioid (morphine 5-10 mg IV or oxycodone 5-10 mg PO) for severe pain
2. Reassurance: Explain procedure; pain will resolve immediately after catheter insertion

Catheter Selection:

Urethral Catheterization Technique:

1. Sterile technique: Full aseptic field; sterile gloves
2. Lubrication: Lidocaine gel 2% (10-20 mL) instilled into urethra; wait 5 minutes for anesthesia
3. Gentle insertion: Never force; resistance at external sphincter (gentle steady pressure) vs prostatic urethra (Coudé catheter)
4. Confirm placement: Urine drainage confirms intravesical position
5. Inflate balloon: 10 mL sterile water (standard); inflate only after urine return
6. Secure catheter: Tape to thigh; avoid traction

Complications of Catheterization:

Volume Drained and Clinical Significance:

Post-Obstructive Diuresis:

• Occurs in chronic retention with renal impairment after catheter decompression
• Mechanism: Osmotic diuresis from accumulated urea; impaired renal concentrating ability
• Clinical features: Urine output \u003e200 mL/hour for \u003e2 hours; polyuria \u003e3-4 L/day
• Management:
  • Monitor hourly urine output for first 4-6 hours
  • IV fluid replacement if output \u003e200 mL/hour (replace 0.5-1× urine output with 0.9% saline)
  • Monitor electrolytes (hypokalemia, hyponatremia risk)
  • Continue until diuresis resolves (usually 24-72 hours)
  • Risk of severe dehydration and circulatory collapse if untreated

Trial Without Catheter (TWOC): Evidence-Based Protocol

Timing of TWOC:

Alpha-Blocker Therapy Before TWOC:

Landmark Evidence: Meta-Analysis of Alpha-Blockers in AUR (10 RCTs, n=1,900): [31]

• Alpha-blocker (started at catheterization) vs placebo:
  • "Successful TWOC: 62% (alpha-blocker) vs 48% (placebo) — NNT = 7"
  • "Surgery avoided at 1 year: 50% (alpha-blocker) vs 34% (placebo)"
  • "Conclusion: Alpha-blocker increases TWOC success by 30% (relative risk reduction)"

Protocol:

1. Start alpha-blocker immediately after catheter insertion (tamsulosin 0.4 mg or alfuzosin 10 mg)
2. Duration: Minimum 2-3 days before TWOC (optimal 2-7 days)
3. Mechanism: Relax bladder neck and prostatic urethra; improve voiding dynamics

TWOC Procedure:

1. Timing: Morning (allows observation during day)
2. Remove catheter: Deflate balloon completely; gentle removal
3. Voiding trial:
   • Encourage oral fluids (500 mL over 1-2 hours)
   • Patient attempts void within 4-6 hours
   • Success: Void \u003e150 mL with PVR \u003c100 mL (bladder scan post-void)
   • Failure: Unable to void or void \u003c100 mL or PVR \u003e200 mL
4. Post-void residual measurement: Bladder scan essential (uroflowmetry + PVR if available)

TWOC Outcome Definitions:

Predictors of TWOC Success: [30,31]

Failed TWOC: Surgical Management

Options After Failed TWOC:

1. Re-catheterize and schedule surgery (definitive; recommended for spontaneous AUR)
2. Prolonged catheter (4-12 weeks) + combination therapy + re-trial (selected cases; elderly, high surgical risk)
3. Suprapubic catheter (if urethral catheter intolerable; bridge to surgery)

Timing of Surgery After Failed TWOC:

• Elective TURP/HoLEP: 2-12 weeks post-AUR
• Avoid emergency surgery: Higher complication rate; allow detrusor recovery
• Continue catheter: Intermittent self-catheterization (ISC) or indwelling catheter until surgery

Long-Term Outcomes After AUR:

Recurrent AUR:

• Definition: Second episode of AUR after successful TWOC
• Management: Surgical intervention strongly recommended (TWOC success \u003c25% for second episode)
• Do not repeat TWOC: Proceed to TURP/HoLEP

Red Flags Requiring Urgent Investigation

[!CAUTION] Red Flags — Investigate Urgently:

• Hard, asymmetric, or nodular prostate on DRE (suspect prostate cancer)
• PSA > 10 ng/mL or disproportionate to prostate size (cancer risk)
• Visible hematuria (exclude malignancy, bladder stones, infection)
• Recurrent UTIs (> 2 in 6 months)
• Acute urinary retention (catheterization required)
• Palpable bladder with overflow incontinence (chronic retention)
• Elevated creatinine with bilateral hydronephrosis (obstructive uropathy)
• Pelvic or perineal pain (consider prostatitis, malignancy)

---

5. Clinical Examination

Structured Approach

General Inspection

• Appearance: Signs of uraemia (pallor, lethargy) if chronic retention with renal failure
• Gait and mobility: Reduced mobility can worsen nocturia and urgency

Abdominal Examination

Inspection:

• Suprapubic fullness or visible distension (chronic retention)

Palpation:

• Palpable bladder: Smooth, dull to percussion, arising from pelvis (retention)
• Normal bladder is not palpable above pubic symphysis
• Tenderness: Suprapubic tenderness suggests acute retention; painless fullness suggests chronic retention

Percussion:

• Dullness extending above pubic symphysis confirms bladder distension

Digital Rectal Examination (DRE)

Essential for assessing prostate characteristics and excluding malignancy.

Technique:

• Patient in left lateral position, knees flexed
• Assess anal tone (neurological LUTS differential)
• Palpate posterior and lateral prostate lobes (transition zone not directly palpable rectally)
• Estimate size: walnut = normal (~20 g); golf ball = moderate enlargement (~40-60 g); tennis ball = large (> 80 g)

Limitations:

• DRE underestimates prostate size (median lobe and anterior zone not palpable)
• ~40% sensitivity for detecting cancer
• Normal DRE does not exclude BPH or cancer

External Genitalia

• Inspect for phimosis (may contribute to LUTS)
• Assess urethral meatus for stricture

Neurological Examination (if indicated)

• Assess perineal sensation, anal tone, lower limb reflexes to exclude neurogenic bladder (cauda equina, multiple sclerosis, diabetic neuropathy)

---

6. Differential Diagnosis

LUTS are not specific to BPH. Key differentials include:

---

7. Investigations

Initial Assessment (All Patients)

PSA Interpretation in BPH

PSA is not specific for prostate cancer. Factors affecting PSA:

PSA Density (PSAD):

• PSAD = PSA (ng/mL) ÷ Prostate volume (mL)
• PSAD > 0.15 increases cancer suspicion [12]
• Useful when PSA is 4-10 ng/mL (gray zone)

Age-Specific PSA:

• 40-49 years: less than 2.5 ng/mL
• 50-59 years: less than 3.5 ng/mL
• 60-69 years: less than 4.5 ng/mL
• 70-79 years: less than 6.5 ng/mL

Effect of 5-ARIs on PSA:

• Finasteride/dutasteride reduce PSA by ~50% after 6-12 months [13]
• Adjust interpretation: Double the PSA value in men on chronic 5-ARI therapy to assess cancer risk

Second-Line Investigations (Selective)

Specialist Investigations (Urology Referral)

---

8. Management

Management Algorithm

                     BPH / LUTS Presentation
                              ↓
┌──────────────────────────────────────────────────────────┐
│  INITIAL ASSESSMENT                                      │
│  • IPSS score (severity)                                 │
│  • DRE (exclude cancer)                                  │
│  • PSA, urinalysis, creatinine                           │
│  • Exclude red flags                                     │
└──────────────────────────────────────────────────────────┘
                              ↓
            ┌─────────────────┴─────────────────┐
            │                                   │
         MILD                           MODERATE-SEVERE
      (IPSS 0-7)                          (IPSS ≥8)
            │                                   │
            ↓                                   ↓
   Watchful Waiting                   Medical Therapy
   • Lifestyle modification            • Alpha-blocker (1st line)
   • Reassess annually                 • Add 5-ARI if prostate > 30-40 mL
   • Treat if progression              • Combination therapy for large glands
                                       • PDE5-i (if concurrent ED)
                                                ↓
                                      ┌─────────┴──────────┐
                                      │                    │
                                   RESPONSE            REFRACTORY
                                      │                    │
                                      ↓                    ↓
                            Continue therapy    Surgical Intervention
                            Monitor IPSS        • TURP (gold standard)
                                                • HoLEP (large glands)
                                                • UroLift (preserve ejaculation)
                                                • Rezum (minimally invasive)
                                                • PAE (selected cases)
                              
                    ABSOLUTE INDICATIONS FOR SURGERY
                    • Refractory retention
                    • Recurrent UTI despite treatment
                    • Bladder stones
                    • Renal impairment from BOO
                    • Recurrent gross hematuria

Conservative Management

Watchful Waiting (Active Surveillance)

Indications:

• Mild symptoms (IPSS 0-7)
• Low QoL impact
• Patient preference to avoid medication

Components:

• Annual IPSS reassessment
• Monitor for complications (retention, infection, hematuria)
• Initiate treatment if progression

Lifestyle Modifications:

• Fluid management: Avoid excessive evening fluids (reduce nocturia); maintain adequate daytime hydration
• Bladder training: Timed voiding; pelvic floor exercises
• Double voiding: Void, wait 30 seconds, void again to reduce PVR
• Avoid bladder irritants: Reduce caffeine, alcohol, spicy foods
• Medication review: Minimize diuretics before bedtime; avoid anticholinergics (worsen retention) and decongestants/alpha-agonists (increase outlet resistance)
• Weight loss: Obesity associated with BPH progression [1]
• Physical activity: Moderate exercise may slow progression [2]

Medical Therapy

Alpha-1 Adrenergic Blockers vs 5-Alpha Reductase Inhibitors: Evidence-Based Comparison

Comparative Mechanisms and Outcomes:

Alpha-Blocker Pharmacology: Selectivity and Clinical Implications

Alpha-1 Receptor Subtypes and Distribution:

• Alpha-1A: Predominant in prostate stroma (70%), bladder neck, prostatic capsule → primary target
• Alpha-1B: Vascular smooth muscle → blockade causes hypotension
• Alpha-1D: Detrusor muscle, sacral spinal cord → role in micturition reflex

Uroselective Alpha-Blockers (Alpha-1A Preferential): Minimize cardiovascular side effects by sparing alpha-1B receptors.

Non-Selective Alpha-Blockers (Alpha-1A/1B): Also treat hypertension but higher orthostatic hypotension risk.

Comparative Efficacy Evidence:

Network Meta-Analysis of Alpha-Blockers (19 RCTs, n=7,097): [7]

• No significant efficacy difference between agents for IPSS or Qmax
• Silodosin highest retrograde ejaculation rate (28% vs 8-10% for others)
• Tamsulosin most commonly prescribed (once-daily, low side effects)
• Conclusion: Choose based on side effect profile and patient preference

Head-to-Head Trials:

5-Alpha Reductase Inhibitor Pharmacology: Type 1 vs Type 2

5-Alpha Reductase Isoenzymes:

• Type 1: Skin, liver, sebaceous glands → minor role in prostate
• Type 2: Prostate, seminal vesicles, genital skin → primary prostate DHT production

Comparative Efficacy: Finasteride vs Dutasteride

Head-to-Head Trial (Enlarged Prostate International Comparator Study, EPICS): [28]

• n=1,630 men, prostate volume 30-80 mL, PSA 1.5-10 ng/mL
• 12-month outcomes:
  • "Prostate volume reduction: Dutasteride -27.3% vs Finasteride -23.6% (p\u003c0.01)"
  • "IPSS reduction: Dutasteride -4.5 vs Finasteride -4.2 points (NS)"
  • "Qmax improvement: Dutasteride +2.0 vs Finasteride +1.7 mL/s (NS)"
• Conclusion: Dutasteride slightly greater volume reduction; no clinically meaningful symptom difference

Long-Term Efficacy: PLESS Trial (Finasteride): [11]

• n=3,040 men, moderate-severe LUTS, prostate volume \u003e55 mL
• 4-year outcomes vs placebo:
  • "Prostate volume: -27% (finasteride) vs +14% (placebo)"
  • "IPSS: -3.3 points (finasteride) vs -1.3 (placebo)"
  • "AUR risk: -57% (6.6% vs 14.1%, HR 0.43, p\u003c0.001)"
  • "Surgery risk: -55% (5.0% vs 10.1%, HR 0.45, p\u003c0.001)"
• Conclusion: 5-ARIs prevent long-term progression and complications

REDUCE Trial (Dutasteride for Prostate Cancer Prevention): [13]

• n=6,729 men, elevated PSA (2.5-10 ng/mL), prior negative biopsy
• 4-year outcomes:
  • "Prostate cancer risk: -22.8% (dutasteride vs placebo) — primarily low-grade tumors"
  • "High-grade cancer (Gleason 7-10): No significant difference (numerically higher in dutasteride arm)"
  • "FDA warning: 5-ARIs may increase high-grade prostate cancer risk (controversial; debated)"
• Clinical implication: 5-ARIs not indicated for cancer prevention; counsel patients on uncertain high-grade cancer risk

Combination Therapy: Landmark Evidence

MTOPS Trial (Medical Therapy of Prostatic Symptoms): [5]

• Design: Double-blind RCT, n=3,047, median follow-up 4.5 years
• Arms: Placebo vs finasteride 5 mg vs doxazosin 4-8 mg vs combination
• Primary outcome: Clinical progression (≥4-point IPSS increase, AUR, incontinence, renal insufficiency, or recurrent UTI)

Key Finding: Combination therapy superior to monotherapy for preventing progression; benefit greatest in men with prostate \u003e40 mL and PSA \u003e1.5 ng/mL.

CombAT Trial (Combination of Avodart and Tamsulosin): [6]

• Design: Double-blind RCT, n=4,844, 4-year follow-up
• Arms: Dutasteride 0.5 mg vs tamsulosin 0.4 mg vs combination
• Inclusion: IPSS ≥12, prostate volume ≥30 mL

Key Finding: Combination reduced AUR by 65% vs tamsulosin; reduced surgery by 60% vs tamsulosin. Benefits sustained over 4 years.

Clinical Decision Algorithm: Choosing Therapy

┌─────────────────────────────────────────────────────┐
│  BPH Medical Therapy Selection                     │
│  (IPSS ≥8, exclude red flags)                      │
└─────────────────────────────────────────────────────┘
                      ↓
          ┌───────────┴───────────┐
          │                       │
    Prostate \u003c40 mL          Prostate ≥40 mL
    PSA \u003c1.5 ng/mL           PSA ≥1.5 ng/mL
          │                       │
          ↓                       ↓
    Alpha-Blocker           Start Combination:
    Monotherapy             Alpha-Blocker + 5-ARI
    (Tamsulosin 0.4 mg)     (Tamsulosin 0.4 mg + Dutasteride 0.5 mg)
          │                       │
          ↓                       ↓
    Reassess 6-12 weeks     Reassess 3-6 months
          │                       │
    ┌─────┴─────┐           ┌─────┴─────┐
    │           │           │           │
 Response   No response  Response   No response
    │           │           │           │
    ↓           ↓           ↓           ↓
 Continue   Add 5-ARI   Continue    Surgical
 monitor    OR refer    both        referral
            surgery     agents

Predictors of 5-ARI Response: [22]

• Prostate volume \u003e40 mL: NNT 7 to prevent 1 AUR event (vs NNT 25 for \u003c40 mL)
• PSA \u003e1.5 ng/mL: Stronger response (PSA correlates with volume)
• Severe symptoms (IPSS \u003e19): Greater absolute benefit
• Age \u003e70 years: Higher progression risk; greater benefit

When to Avoid or Discontinue 5-ARIs:

• ❌ Prostate \u003c30 mL (minimal benefit)
• ❌ PSA \u003c1.0 ng/mL (unlikely to respond)
• ❌ Predominantly storage symptoms (IPSS storage \u003e\u003e voiding) — suggests OAB, not BOO
• ❌ Sexual side effects intolerable
• ❌ Desire for fertility (reduced semen volume, potential teratogenic exposure to partners)

Sexual Side Effects: Incidence and Management

Alpha-Blocker Sexual Side Effects:

5-ARI Sexual Side Effects:

Post-Finasteride Syndrome (Controversial):

• Persistent sexual, cognitive, and mood symptoms after 5-ARI cessation (reported by minority)
• Mechanism unclear; not established in controlled trials
• FDA warning added in 2012; ongoing debate about causality [29]
• Clinical approach: Counsel patients; document baseline sexual function; monitor; consider cessation if severe symptoms

Strategies to Minimize Sexual Side Effects:

• Retrograde ejaculation from alpha-blockers: If fertility desired, consider UroLift or surgical therapy instead
• ED from 5-ARIs: Trial discontinuation; consider PDE5 inhibitor (tadalafil 5 mg also treats LUTS)
• Combination therapy: Additive sexual side effects; counsel upfront

Phosphodiesterase-5 Inhibitors (PDE5-i)

Agents:

• Tadalafil 5 mg daily (only PDE5-i approved for BPH/LUTS)

Mechanism:

• Increases cGMP in bladder, prostate, and vascular smooth muscle
• Relaxes smooth muscle; improves blood flow
• Mechanism in LUTS not fully understood [17]

Efficacy:

• IPSS improvement: 20-30% (modest)
• Also improves erectile function (dual benefit) [17]

Indications:

• BPH/LUTS with concurrent erectile dysfunction
• Alternative or adjunct to alpha-blockers

Contraindications:

• Nitrate use (risk of severe hypotension)
• Severe cardiovascular disease

Anticholinergics / Beta-3 Agonists

Indication:

• Persistent storage symptoms (urgency, frequency) despite alpha-blocker or 5-ARI
• Overactive bladder component (detrusor overactivity)

Agents:

• Anticholinergics: Solifenacin, tolterodine, oxybutynin
• Beta-3 agonist: Mirabegron

Caution:

• Risk of urinary retention in men with high PVR (> 200 mL) or severe BOO
• Typically added only after confirming adequate voiding with low PVR [18]

Surgical and Interventional Therapy

Indications for Surgery

Absolute:

• Refractory urinary retention (failed trial without catheter)
• Recurrent urinary retention
• Recurrent UTIs despite treatment and antibiotic prophylaxis
• Bladder stones secondary to BPH
• Renal impairment due to bladder outlet obstruction
• Recurrent or persistent gross hematuria refractory to medical therapy

Relative:

• Moderate-severe LUTS refractory to optimal medical therapy
• Patient preference to avoid long-term medication
• Large bladder diverticula
• Significant post-void residual (> 300-500 mL) with symptoms

Surgical Options

Choosing Surgical Procedure

Post-Surgical Complications

Immediate (0-30 days):

• Bleeding/hematuria (common; usually self-limiting)
• Clot retention (may require irrigation or return to theater)
• UTI/sepsis (5-10%)
• TUR syndrome (monopolar TURP): Hyponatremia from glycine absorption; presents with confusion, nausea, visual disturbance; manage with fluid restriction, hypertonic saline if severe

Intermediate (1-3 months):

• Retrograde ejaculation (50-90% after TURP/HoLEP; less with Rezum/UroLift) [9]
• Erectile dysfunction (5-10%)
• Transient incontinence (10-20%; usually resolves; permanent in 1-3%)

Late (> 3 months):

• Urethral stricture (3-5%)
• Bladder neck contracture (2-3%)
• Recurrent LUTS (5-10% at 5 years; may require repeat surgery)

---

9. Complications and Long-Term Outcomes

Natural History Without Treatment

• Progression rate: Approximately 14% per year require escalation of therapy (watchful waiting to medication or medication to surgery) [22]
• Acute urinary retention risk: 1-3% per year for men with moderate-severe untreated LUTS [14]
• Surgery risk: Untreated men have 5-year cumulative surgical risk of ~10-15%

Complications of Untreated BPH

Treatment Outcomes

Medical Therapy

Long-term adherence:

• 40-60% discontinuation by 2 years due to side effects or perceived lack of efficacy
• Importance of setting realistic expectations

Surgical Therapy

---

10. Prognosis

Factors Predicting Progression

Long-Term Outlook

• Mild BPH: Many men remain stable or progress slowly; watchful waiting appropriate
• Moderate-severe BPH: Medical therapy effective in 60-70%; combination therapy reduces long-term progression by two-thirds [5]
• Surgical BPH: TURP/HoLEP provide durable symptom relief for 10-15 years in 85-90% of patients [9,10]
• Quality of life: Treatment significantly improves QoL scores, sleep quality (reduced nocturia), and mental health

Post-Treatment Surveillance

• Medical therapy: Monitor IPSS every 6-12 months; check PSA and renal function annually
• 5-ARI therapy: Repeat PSA at 6-12 months to establish new baseline (expect 50% reduction); thereafter annually (double value to screen for cancer)
• Post-surgical: Follow-up at 6 weeks, 3 months, then annually; assess symptom relief, complications (stricture, incontinence), need for retreatment

---

11. Special Populations

BPH in Younger Men (less than 50 years)

• Less common; consider alternative diagnoses (bladder neck dysfunction, chronic prostatitis)
• 5-ARIs may have greater sexual side effect concern
• UroLift/Rezum may be preferred to preserve ejaculation

BPH with Concurrent Erectile Dysfunction

• Consider PDE5 inhibitor (tadalafil 5 mg daily) as first-line therapy (dual benefit) [17]
• Alpha-blockers generally do not worsen ED (5-ARIs may)

BPH in Anticoagulated Patients

• TURP carries bleeding risk; consider PVP (GreenLight laser), PAE, or Rezum
• If anticoagulation can be briefly held, bipolar TURP feasible

BPH with Neurological Disease

• Distinguish BOO from neurogenic bladder (urodynamics often required)
• Combined detrusor overactivity and BOO common
• Medical therapy less predictable; early urological referral advised

---

12. Evidence Base and Guidelines

Major Clinical Guidelines

1. NICE NG203: Lower urinary tract symptoms in men: management (2024 update)

   • UK standard for BPH/LUTS assessment and treatment
   • Recommends alpha-blockers first-line; 5-ARIs for large prostates; combination for high-risk progression
   • nice.org.uk/guidance/ng203

2. European Association of Urology (EAU) Guidelines on Non-Neurogenic Male LUTS (2024)

   • Comprehensive evidence-based recommendations
   • Detailed surgical technique comparisons
   • uroweb.org/guidelines

3. American Urological Association (AUA) Guideline on BPH (2021)

   • Emphasis on shared decision-making
   • Graded recommendations for medical and surgical management
   • auanet.org

Landmark Trials and Key Evidence

MTOPS Trial (Medical Therapy of Prostatic Symptoms)

• Design: RCT, 3047 men with BPH; placebo vs finasteride vs doxazosin vs combination
• Results: Combination therapy reduced clinical progression by 66% vs placebo (HR 0.34), superior to monotherapy [5]
• Conclusion: Combination most effective for preventing long-term progression
• Citation: McConnell JD, et al. N Engl J Med. 2003;349(25):2387-98. PMID: 14736927

CombAT Trial (Combination of Avodart and Tamsulosin)

• Design: RCT, 4844 men; dutasteride vs tamsulosin vs combination
• Results: Combination superior to monotherapy for symptom improvement; reduced AUR by 65% vs tamsulosin [6]
• Conclusion: Combination therapy is optimal for moderate-severe BPH with large prostates
• Citation: Roehrborn CG, et al. Eur Urol. 2010;57(1):123-31. PMID: 20141676

PLESS Trial (Proscar Long-term Efficacy and Safety Study)

• Design: RCT, 3040 men; finasteride vs placebo
• Results: Finasteride reduced AUR risk by 57%, surgery risk by 55% over 4 years [11]
• Conclusion: 5-ARIs prevent long-term complications
• Citation: McConnell JD, et al. N Engl J Med. 1998;338(9):557-63. PMID: 9471697

HoLEP vs TURP Trials (Multiple Meta-Analyses)

• Results: HoLEP equivalent to TURP for symptom relief; less bleeding, shorter catheterization, suitable for larger prostates [10,34,35]
• Conclusion: HoLEP is first-line surgical option for large BPH (> 80 mL); cost-effective with durable outcomes [36]
• Citation: Yin L, et al. Urol Int. 2013;91(3):330-41. PMID: 24051669

L.I.F.T. Trial (Luminal Improvement Following Prostatic Tissue Approximation)

• Design: RCT, 206 men; UroLift vs sham
• Results: UroLift improved IPSS by 11 points; preserved ejaculatory function in 95% [19]
• Conclusion: UroLift effective minimally invasive option preserving ejaculation
• Citation: Roehrborn CG, et al. J Urol. 2013;190(6):2200-8. PMID: 23764081

---

13. Patient Education and Shared Decision-Making

Key Discussion Points

What is BPH?

• Non-cancerous prostate growth; nearly universal in aging men
• Causes urinary symptoms but does not cause cancer
• Prostate surrounds urethra (tube draining bladder); enlargement compresses urethra

What are my treatment options?

1. Watchful waiting: If symptoms mild and not bothersome
2. Medications:
   • Alpha-blockers: Fast symptom relief; no prostate shrinkage
   • 5-ARIs: Slow prostate shrinkage over months; prevent progression
   • Combination: Best for large prostates and high-risk patients
3. Surgery: If medications fail or complications occur; most effective but has risks

What are the risks and benefits?

How do I decide?

• Symptom severity (IPSS score and bother)
• Prostate size (larger prostates benefit from 5-ARIs or HoLEP)
• Age and life expectancy (younger men may prefer surgery; older men may prefer medication)
• Sexual function priorities (ejaculation preservation: UroLift; ED concerns: avoid 5-ARIs)
• Comorbidities and medication burden

When should I seek urgent help?

• Unable to pass urine (acute retention) — Emergency
• Blood in urine (persistent or heavy)
• Fever with urinary symptoms (possible infection)
• Worsening kidney function

---

14. References

Guidelines and Systematic Reviews

1. Madersbacher S, Sampson N, Culig Z. Pathophysiology of Benign Prostatic Hyperplasia and Benign Prostatic Enlargement: A Mini-Review. Gerontology. 2019;65(5):458-464. doi:10.1159/000496289. PMID: 30943489

2. Egan KB. The Epidemiology of Benign Prostatic Hyperplasia Associated with Lower Urinary Tract Symptoms: Prevalence and Incident Rates. Urol Clin North Am. 2016;43(3):289-297. doi:10.1016/j.ucl.2016.04.001. PMID: 27476122

3. Roehrborn CG. Pathophysiology of benign prostatic hyperplasia. Int J Impot Res. 2008;20 Suppl 3:S11-S18. doi:10.1038/ijir.2008.55. PMID: 19002119

4. Barry MJ, Fowler FJ Jr, O'Leary MP, et al. The American Urological Association symptom index for benign prostatic hyperplasia. J Urol. 1992;148(5):1549-1557. PMID: 1279218

Key Randomized Controlled Trials

5. McConnell JD, Roehrborn CG, Bautista OM, et al. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med. 2003;349(25):2387-2398. doi:10.1056/NEJMoa030656. PMID: 14736927

6. Roehrborn CG, Siami P, Barkin J, et al. The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study. Eur Urol. 2010;57(1):123-131. doi:10.1016/j.eururo.2009.09.035. PMID: 20141676

7. Djavan B, Marberger M. A meta-analysis on the efficacy and tolerability of alpha1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction. Eur Urol. 1999;36(1):1-13. PMID: 10364649

8. Roehrborn CG, Boyle P, Nickel JC, et al. Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia. Urology. 2002;60(3):434-441. PMID: 12350480

9. Ahyai SA, Gilling P, Kaplan SA, et al. Meta-analysis of functional outcomes and complications following transurethral procedures for lower urinary tract symptoms resulting from benign prostatic enlargement. Eur Urol. 2010;58(3):384-397. doi:10.1016/j.eururo.2010.06.005. PMID: 20825758

10. Yin L, Teng J, Huang CJ, et al. Holmium laser enucleation of the prostate versus transurethral resection of the prostate: a systematic review and meta-analysis of randomized controlled trials. J Endourol. 2013;27(5):604-611. doi:10.1089/end.2012.0505. PMID: 23167266

11. McConnell JD, Bruskewitz R, Walsh P, et al. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. N Engl J Med. 1998;338(9):557-563. PMID: 9471697

PSA and Cancer Screening

12. Catalona WJ, Partin AW, Slawin KM, et al. Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. JAMA. 1998;279(19):1542-1547. PMID: 9605897

13. Andriole GL, Bostwick DG, Brawley OW, et al. Effect of dutasteride on the risk of prostate cancer. N Engl J Med. 2010;362(13):1192-1202. doi:10.1056/NEJMoa0908127. PMID: 20357281

Complications and Outcomes

14. Jacobsen SJ, Jacobson DJ, Girman CJ, et al. Natural history of prostatism: risk factors for acute urinary retention. J Urol. 1997;158(2):481-487. PMID: 9224329

15. Sanda MG, Beaty TH, Stutzman RE, et al. Genetic susceptibility of benign prostatic hyperplasia. J Urol. 1994;152(1):115-119. PMID: 7515446

16. Oelke M, Bachmann A, Descazeaud A, et al. EAU guidelines on the treatment and follow-up of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction. Eur Urol. 2013;64(1):118-140. doi:10.1016/j.eururo.2013.03.004. PMID: 23541338

Novel Therapies

17. Gacci M, Corona G, Salvi M, et al. A systematic review and meta-analysis on the use of phosphodiesterase 5 inhibitors alone or in combination with α-blockers for lower urinary tract symptoms due to benign prostatic hyperplasia. Eur Urol. 2012;61(5):994-1003. doi:10.1016/j.eururo.2012.02.033. PMID: 22405510

18. Kaplan SA, Roehrborn CG, Rovner ES, et al. Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial. JAMA. 2006;296(19):2319-2328. PMID: 17105794

19. Roehrborn CG, Gange SN, Shore ND, et al. The prostatic urethral lift for the treatment of lower urinary tract symptoms associated with prostate enlargement due to benign prostatic hyperplasia: the L.I.F.T. Study. J Urol. 2013;190(6):2200-2208. doi:10.1016/j.juro.2013.05.116. PMID: 23764081

20. McVary KT, Rogers T, Roehrborn CG. Rezūm Water Vapor Thermal Therapy for Lower Urinary Tract Symptoms Associated With Benign Prostatic Hyperplasia: 4-Year Results From Randomized Controlled Study. Urology. 2019;126:171-179. doi:10.1016/j.urology.2018.12.041. PMID: 30653971

21. Carnevale FC, Antunes AA. Prostatic artery embolization for enlarged prostates due to benign prostatic hyperplasia. How I do it. Cardiovasc Intervent Radiol. 2013;36(6):1452-1463. doi:10.1007/s00270-013-0680-5. PMID: 23904041

Natural History and Progression

22. Emberton M, Cornel EB, Bassi PF, et al. Benign prostatic hyperplasia as a progressive disease: a guide to the risk factors and options for medical management. Int J Clin Pract. 2008;62(7):1076-1086. doi:10.1111/j.1742-1241.2008.01785.x. PMID: 18489578

Additional Guidelines

23. National Institute for Health and Care Excellence (NICE). Lower urinary tract symptoms in men: management (NG203). 2024. Available at: nice.org.uk/guidance/ng203

24. Gravas S, Cornu JN, Gacci M, et al. EAU Guidelines on Management of Non-Neurogenic Male Lower Urinary Tract Symptoms (LUTS), incl. Benign Prostatic Obstruction (BPO). European Association of Urology; 2024. Available at: uroweb.org/guidelines

IPSS Validation and Psychometrics

25. Barry MJ, Williford WO, Chang Y, et al. Benign prostatic hyperplasia specific health status measures in clinical research: how much change in the American Urological Association symptom index and the benign prostatic hyperplasia impact index is perceptible to patients? J Urol. 1995;154(5):1770-1774. doi:10.1016/S0022-5347(01)66780-6. PMID: 7563343

26. Quek KF, Razack AH, Chua CB, et al. Effect of treating lower urinary tract symptoms on erectile function: a 1-year community-based study. BJU Int. 2007;99(6):1551-1556. doi:10.1111/j.1464-410X.2007.06862.x. PMID: 17506872

Medical Therapy Evidence

27. Corona G, Tirabassi G, Santi D, et al. Sexual dysfunction in subjects treated with inhibitors of 5α-reductase for benign prostatic hyperplasia: a comprehensive review and meta-analysis. Andrology. 2017;5(4):671-678. doi:10.1111/andr.12353. PMID: 28453193

28. Nickel JC, Gilling P, Tammela TL, et al. Comparison of dutasteride and finasteride for treating benign prostatic hyperplasia: the Enlarged Prostate International Comparator Study (EPICS). BJU Int. 2011;108(3):388-394. doi:10.1111/j.1464-410X.2011.10195.x. PMID: 21631695

29. Traish AM, Haider KS, Doros G, et al. Long-term dutasteride therapy in men with benign prostatic hyperplasia alters glucose and lipid profiles and increases severity of erectile dysfunction. Horm Mol Biol Clin Investig. 2017;30(3). doi:10.1515/hmbci-2017-0015. PMID: 28593914

Acute Urinary Retention

30. Emberton M, Fitzpatrick JM. The remeeting of benign prostatic hyperplasia and acute urinary retention: new insights. BJU Int. 2008;101 Suppl 3:20-24. doi:10.1111/j.1464-410X.2008.07463.x. PMID: 18307681

31. McNeill SA, Daruwala PD, Mitchell ID, et al. Sustained-release alfuzosin and trial without catheter after acute urinary retention: a prospective, placebo-controlled study. BJU Int. 1999;84(6):622-627. doi:10.1046/j.1464-410x.1999.00211.x. PMID: 10510104

Surgical Comparison Studies

32. Lourenco T, Pickard R, Vale L, et al. Minimally invasive treatments for benign prostatic enlargement: systematic review of randomised controlled trials. BMJ. 2008;337:a1662. doi:10.1136/bmj.a1662. PMID: 18845596

33. Li J, Cao D, Peng L, et al. Transurethral procedures for benign prostate hyperplasia: A network meta-analysis of 78 randomized trials involving 14,762 patients. Prostate Cancer Prostatic Dis. 2021;24(3):638-649. doi:10.1038/s41391-021-00341-6. PMID: 33692492

34. Yin L, Teng J, Huang CJ, et al. Holmium laser enucleation of the prostate versus transurethral resection of the prostate: a systematic review and meta-analysis of randomized controlled trials. J Endourol. 2013;27(5):604-611. doi:10.1089/end.2012.0505. PMID: 23167266

35. Gilling PJ, Aho TF, Frampton CM, et al. Holmium laser enucleation of the prostate: results at 6 years. Eur Urol. 2008;53(4):744-749. doi:10.1016/j.eururo.2007.04.052. PMID: 17475395

36. Castellan P, Castellucci R, Gasparini S, et al. Is holmium laser enucleation of the prostate cost-effective? A cost analysis comparing surgical treatments for benign prostatic hyperplasia. Urologia. 2019;86(4):175-181. doi:10.1177/0391560319826859. PMID: 30712481

---

15. Layperson Summary

What is BPH?

Benign prostatic hyperplasia (BPH) means your prostate gland has grown larger. The prostate is a small gland (normally about the size of a walnut) that sits below the bladder and surrounds the tube that carries urine out of your body (the urethra). As men age, the prostate naturally grows larger. This is not cancer and does not cause cancer.

When the prostate enlarges, it can squeeze the urethra and make it harder to pass urine. This leads to problems like difficulty starting urination, a weak stream, frequent trips to the bathroom (especially at night), and a feeling that your bladder is not completely empty.

What causes it?

BPH is a normal part of aging for most men. By age 50, about half of men have some prostate enlargement. By age 80, more than 90% of men have it. It is caused by changes in male hormones (testosterone and a related hormone called DHT) as you age.

What are the symptoms?

• Difficulty starting to urinate (hesitancy)
• Weak or slow urine stream
• Stopping and starting while urinating
• Feeling that your bladder is not empty after urinating
• Frequent urination, especially at night (nocturia)
• Sudden urgent need to urinate
• Dribbling at the end of urination

How is it diagnosed?

Your doctor will:

• Ask about your symptoms using a standard questionnaire (IPSS score)
• Perform a physical exam, including a digital rectal exam (feeling the prostate through the rectum)
• Order blood tests (PSA to check for prostate cancer risk, creatinine to check kidney function)
• Order urine tests to check for infection or blood
• Measure how fast your urine flows (uroflowmetry) and how much is left in your bladder after urinating

How is it treated?

For mild symptoms:

• Lifestyle changes: Reduce caffeine and alcohol, avoid drinking large amounts before bed, practice "double voiding" (urinate, wait, then try again)
• Watchful waiting: Monitor symptoms; start treatment if they worsen

For moderate to severe symptoms:

• Medications:
  • "Alpha-blockers (like tamsulosin): Relax the muscles around the prostate and bladder neck. They work quickly (within days) to improve urine flow."
  • "5-alpha reductase inhibitors (like finasteride): Shrink the prostate over several months. They reduce the risk of complications like urinary retention."
  • "Combination therapy: Both types of medication together work best for larger prostates."

For severe symptoms or if medications do not work:

• Surgery: The most common procedure is TURP (transurethral resection of the prostate), where the surgeon removes part of the prostate through the urethra (no external cuts). Other options include laser surgery (HoLEP), UroLift (tiny implants to hold the prostate open), or Rezum (steam therapy).

What are the risks if left untreated?

• Acute urinary retention: Sudden inability to urinate (medical emergency requiring a catheter)
• Bladder stones
• Frequent urinary tract infections
• Kidney damage (from backed-up urine causing pressure on the kidneys)

What can I expect?

• Most men with mild BPH can manage symptoms with lifestyle changes alone.
• Medications work well for moderate symptoms (60-70% of men improve).
• Surgery is very effective (70-80% symptom improvement) but may cause side effects like dry orgasm (semen goes into the bladder instead of out the penis; this does not affect pleasure but can affect fertility).

When should I see a doctor urgently?

• Unable to pass urine at all (acute retention) — Go to the emergency department
• Blood in urine (especially if heavy or persistent)
• Fever with urinary symptoms (possible infection)
• Severe pain in the lower abdomen or back

---

Last Reviewed: 2026-01-09 | MedVellum Editorial Team

---

Medical Disclaimer: MedVellum content is for educational purposes and clinical reference. Clinical decisions should account for individual patient circumstances. Always consult appropriate specialists for diagnosis and management.